A PHASE I/II STUDY OF 177LU-HTK03170 IN METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER SUBJECTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN-POSITIVE DISEASE
- Registry ID
- H22-02395
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY
- Start date
- 2023-11-30
- Last update
- 2022-12-08
Conditions
- CASTRATION RESISTANT PROSTATE CANCER
- PROSTATE CANCER
Related clinical trials
- A PHASE I/II OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD6621, A T -CELL-ENGAGING ANTIBODY THAT TARGETS STEAP2, CD3, AND CD8 IN ADULT PARTICIPANTS WITH METASTATIC PROSTATE CANCER (ACTIVATED-4-PC)
- Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE OPTIMIZATION STUDY OF GSK5471713 IN ADULT PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
- A PHASE II, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF THE COMBINATION OF INAVOLISIB PLUS ENZALUTAMIDE VERSUS PHYSICIAN'S CHOICE OF ARPI OR DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER
- A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND
EXPANSION STUDY OF GSK5458514 PSMA TARGETING T CELL ENGAGER ALONE OR IN
COMBINATION WITH OTHER ANTI-CANCER AGENTS IN ADULT PARTICIPANTS WITH METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
- A MULTINATIONAL, MULTICENTER, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPENLABEL,
PHASE 3 STUDY OF LUTETIUM (177LU) ROSOPATAMAB TETRAXETAN IN COMBINATION WITH
STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN PATIENTS WITH PROSTATE-SPECIFIC
MEMBRANE ANTIGEN (PSMA) POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE
CANCER (MCRPC) AFTER ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) TREATMENT
View on source registry